Table 1.
Centrally acting marketed or compounds in clinical development for the treatment of obesity
| Company | Product name/code | Product type | Phase |
|---|---|---|---|
| Abbott | Sibutramine | NA/5HT reuptake inhibitor | Authorized |
| Arena Pharma | Lorcaserin | 5HT2C agonist | Phase III |
| Athersys | ATHX-105 | 5HT2C agonist | Phase I |
| Biovitrum | BVT.74316 | 5HT6 antagonist | Phase I |
| Dov Pharmaceuticals | Dov 21947 | NA/DA/5HT reuptake inhibitor | Phase II |
| EPIX Pharma | PRX-07034 | 5HT6 antagonist | Phase I |
| NeuroSearch | Tesofensine | NA/DA/5HT reuptake inhibitor | Phase II |
| Orexigen | Contrave | Bupropion + naltrexone | Phase III |
| Orexigen | Empatic | Bupropion + zonisamide | Phase II |
| Shionogi | S-2367 | Neuropeptide Y5 inhibitor | Phase II |
| Vivus | Qnexa | Phentermine + topiramate | Phase II |